Pinsent Masons Advises Accord Healthcare in Exclusive Licence Agreement with Myovant Sciences to Commercialise ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
14 Jun 2022 | 03:35 pm |
Pinsent Masons represented Accord Healthcare Ltd in an exclusive license agreement with Myovant Sciences to commercialise relugolix, Myovant’s advanced hormone-sensitive prostate cancer treatment, under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey.
Under the terms of the agreement, Myovant will receive an upfront payment of US$50 million, and is eligible to receive milestones which could total up to a further US$90.5 million. Myovant will continue to lead the global development of relugolix and provide initial product supply to Accord. Accord will be responsible for certain local clinical development, all commercialization for its territories, and has the option to manufacture relugolix in the future.
The Pinsent Masons transactions team was led by Life Sciences Transactions partner Gina Bicknell, with primary support from solicitor Kiah York and legal director Mario Subramaniam.
Latest press releases
Show me all press releasesPinsent Masons appoints infrastructure M&A specialist Candice Lambeth
Multinational law firm Pinsent Masons has today announced the appointment of Candice Lambeth as a partner in its corporate team in London.
Pinsent Masons bolsters Middle East International Arbitration practice with partner hire
Multinational law firm Pinsent Masons has appointed Shanelle Irani as a partner in its International Arbitration team in Dubai, further strengthening the firm's capability in high-value commercial and investor-state disputes across the region.
Pinsent Masons hires leading IP partner duo Kai Ruting and Philipp Widera in Germany
Multinational law firm Pinsent Masons has appointed intellectual property (IP) partners Dr. Kai Rüting, LL.M. and Philipp Widera, LL.M. to join its Düsseldorf office.
People who viewed this press release also viewed
Show me all press releasesPinsent Masons advises Horizon 3 Healthcare on investment in Xeltis
Multinational law firm Pinsent Masons has advised Horizon 3 Healthcare as lead investor in an additional €20.5 million funding round for Xeltis, a clinical-stage medtech company developing transformative implantable medical devices.
Pinsent Masons elects John Maciver as Senior Partner
Multinational law firm Pinsent Masons has elected John Maciver as Senior Partner.
Pinsent Masons strengthens its competition law practice with the appointment of Christian Peeters
Multinational law firm Pinsent Masons is strengthening its Antitrust, Competition & Trade practice at its Dusseldorf/Germany office with the appointment of Christian Peeters, LL.M., effective 1 July 2026.
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on
Location contacts
Europe: [email protected]
Asia: [email protected]
Middle East: [email protected]
Australia: [email protected]